Welcome to our dedicated page for Opthea American Depositary Shares news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea American Depositary Shares stock.
Opthea Limited (symbol: OPT) is a pioneering Australian biotechnology company dedicated to developing innovative biologic therapies for eye diseases. With a strong focus on medical technology and healthcare, Opthea's primary mission is to address unmet medical needs through advanced therapeutic solutions.
Opthea's flagship product, OPT-302, is a groundbreaking biologic treatment designed to inhibit VEGF-C and VEGF-D, which are critical factors in abnormal blood vessel growth and leakage. These mechanisms are commonly associated with eye conditions such as wet age-related macular degeneration (wet AMD). Currently, OPT-302 is undergoing a Phase 1/2a clinical trial to evaluate its safety and efficacy in patients suffering from wet AMD, marking a significant milestone in the company's development pipeline.
The company's robust intellectual property portfolio underpins its research and development efforts, covering essential targets like VEGF-C, VEGF-D, and VEGF Receptor-3. These assets form the foundation of Opthea's strategy to develop advanced treatments aimed at reducing vascular leakage and managing diseases linked to blood and lymphatic vessel growth.
Recent achievements underscore Opthea's commitment to advancing its clinical programs. The company has launched a fully underwritten Retail Entitlement Offer, inviting eligible retail shareholders in Australia and New Zealand to participate. This initiative is part of Opthea's broader strategy to secure funding and support the continued development of OPT-302.
Participants in the Placement and Entitlement Offer will receive new options, each exercisable at A$0.80, set to expire on 31 August 2025. These options are expected to be quoted on the ASX, providing additional investment opportunities for shareholders.
Investment in biotechnology firms like Opthea entails inherent risks, including the lengthy clinical trial process, patent protection uncertainties, and rapid technological advancements. However, Opthea's focused approach and strategic partnerships position it as a promising player in the biotech space. For detailed information on participation and investment opportunities, refer to the Prospectus available on the ASX website and Opthea's official site.
For more updates and information, investors and media can contact:
Media: Hershel Berry (hberry@bplifescience.com)
Investor: PJ Kelleher (pkelleher@lifesciadvisors.com)
Opthea (ASX/NASDAQ: OPT) announced the appointment of Kathy Connell as Non-Executive Director to its Board, effective November 15, 2024. Connell brings extensive commercial and business development expertise across healthcare industries. The appointment comes as Opthea prepares for Phase 3 wet AMD topline data expected in 2025. Simultaneously, Megan Baldwin retired from the Board as Executive Director but will continue as Founder and Chief Innovation Officer. Connell currently serves as Senior Client Partner at Korn Ferry and holds board positions at Avecho Biotechnology, Proto Axiom, and BioNSW.
Opthea (ASX/NASDAQ: OPT) announced its participation in two major ophthalmology conferences where sozinibercept will be featured. At the 17th Congress of APVRS, Dr. Gregg T. Kokame will present Phase 2b trial data showing that patients with polypoidal choroidal vasculopathy treated with a combination of sozinibercept and ranibizumab achieved significantly better visual and anatomic outcomes compared to ranibizumab alone at 24 weeks. Additionally, CEO Frederic Guerard will present at the Ophthalmology Innovation Summit XIV during the Retina Innovation Showcase.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases including wet AMD, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Virtual Bell Potter Healthcare Conference on November 18, 2024, at 3:00 PM AEDT, with CEO Frederic Guerard delivering the presentation. Additionally, Guerard will participate in one-on-one meetings at the Jefferies London Healthcare Conference on November 19, 2024. The Bell Potter presentation will be available for viewing in the Investor Relations section of Opthea's website.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has filed its Notice of Annual General Meeting. Dr. Megan Baldwin, Executive Director, will retire from the Board at the conclusion of the annual general meeting on November 15, 2024, and has chosen not to seek re-election. Dr. Baldwin will continue her role as Founder and Chief Innovation Officer, focusing on advancing Opthea's innovation agenda.
The company is approaching anticipated sozinibercept wet AMD Phase 3 data readouts in 2025. Dr. Baldwin expressed pride in sozinibercept's potential as a breakthrough for wet AMD patients. Chairman Jeremy Levin acknowledged Dr. Baldwin's valuable contributions to the Board. Opthea is currently seeking a new director to fill the upcoming Board vacancy.
Opthea (ASX/NASDAQ: OPT) announced that its wet age-related macular degeneration (wet AMD) program will be presented at the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. Dr. David Boyer will provide an update on sozinibercept, highlighting:
- The unmet medical need in wet AMD
- Phase 2b trial results
- Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy
The presentation, titled 'Update on OPT-302 (sozinibercept)', is scheduled for 5:27 PM CT during Session 4: New Routes and New Molecules. Innovate Retina focuses on innovations in retina care, including AMD management, ocular imaging, gene therapy, and advances in retinal pharmacotherapy.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has announced three key appointments as it prepares for sozinibercept Phase 3 topline data readouts in 2025:
1. Dr. Parisa Zamiri as Chief Medical Officer (CMO), overseeing clinical development, regulatory affairs, and medical affairs.
2. Tom Reilly as Chief Financial Officer (CFO), bringing over 25 years of experience in finance and administration in life sciences.
3. Anand Sundaram as Vice President Marketing, with extensive commercial experience in retina and other therapeutic areas.
These appointments aim to strengthen Opthea's leadership in preparation for anticipated data readouts from the COAST trial in early Q2 2025 and the ShORe trial in mid-2025, followed by regulatory submissions globally.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on novel therapies for retinal diseases like wet age-related macular degeneration (wet AMD), has announced its participation in the UBS Virtual Ophthalmology Day 2024. The event is scheduled for October 2, 2024.
Key details of Opthea's participation include:
- A fireside chat on Wednesday, October 2, 2024, at 4:00 PM ET
- CEO Frederic Guerard, PharmD, will be the presenter
- One-on-one investor meetings will be available
- A webcast link is provided for access to the fireside chat
The webcast will also be accessible through the 'Events & Presentations' section of Opthea's Investor Relations webpage at www.opthea.com.
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing therapies for retinal diseases, has been added to the S&P/ASX 300 Index effective September 23, 2024. This inclusion reflects the company's strengthened balance sheet following a financing round in July 2024 and the completion of enrollment for its Phase 3 wet AMD program with nearly 2,000 patients.
CEO Frederic Guerard highlighted that joining the index may diversify Opthea's institutional shareholder base as the company progresses towards anticipated topline data readouts from its COAST and ShORe trials in Q2 and mid-2025, respectively. The company is also preparing for a potential US FDA approval and product launch.
The S&P/ASX 300 Index measures the performance of 300 of Australia's largest securities by float-adjusted market capitalization, encompassing large-cap, mid-cap, and small-cap components.
Opthea (ASX/NASDAQ: OPT) has successfully completed its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, a potential treatment for wet age-related macular degeneration (wet AMD). The campaign involved producing three consecutive commercial-scale drug substance batches, validating Opthea's manufacturing process. This achievement is a significant milestone towards a potential Biologics License Application (BLA) filing for sozinibercept in wet AMD.
CEO Fred Guerard emphasized that this success demonstrates the company's ability to consistently manufacture quality drug substance at commercial scale, a important component for the BLA Chemistry, Manufacturing and Controls (CMC) module. Opthea is now well-positioned to supply its planned drug product PPQ campaign and initial launch materials. A progress update on the drug product PPQ campaign is expected in early 2025.
Opthea (ASX/NASDAQ: OPT) announced its participation in the 24th EURETINA Congress and EURETINA Innovation Spotlight in Barcelona, Spain. The company will present scientific data and host a non-CME educational lunch symposium highlighting sozinibercept's potential to improve visual outcomes in wet AMD patients. Key presentations include:
1. Sozinibercept in wet AMD: Potential for superior vision outcomes beyond anti-VEGF-A therapies
2. Intravitreal sozinibercept combined with ranibizumab for polypoidal choroidal vasculopathy treatment
3. VEGF-A/C/D inhibition with sozinibercept and ranibizumab combination therapy for nAMD
Opthea's Phase 3 pivotal program evaluating sozinibercept combination therapy in wet AMD has completed patient enrollment. Topline data for the COAST study is expected in early Q2 CY2025, and for the ShORe study in mid-year CY 2025.
FAQ
What is the current stock price of Opthea American Depositary Shares (OPT)?
What is the market cap of Opthea American Depositary Shares (OPT)?
What does Opthea Limited specialize in?
What is OPT-302?
What stage is OPT-302 currently in?
How does Opthea fund its clinical programs?
What is the significance of VEGF-C and VEGF-D in Opthea's research?
How can investors participate in Opthea's funding offers?
What risks are associated with investing in Opthea?
Where can I find more information about Opthea’s developments?
Who can I contact for media inquiries about Opthea?
Who can I contact for investor inquiries about Opthea?
